Table 1 Baseline characteristics of patients who were eligible for the observational study
Characteristic | Treatment regimena | ||
|---|---|---|---|
Iloprost/sildenafil | Sildenafil/iloprost | Iloprost + sildenafil | |
n = 61 | n = 63 | n = 24 | |
Female sex, % | 65.0 | 66.7 | 78.3 |
[n = 60] | [n = 60] | [n = 23] | |
Mean age at diagnosis, years (SD) | 48.7 (14.9) | 53.0 (15.2) | 43.3 (17.1) |
Classification of PH, n (%) | |||
Idiopathic PAH | 21 (35.0) | 15 (25.0) | 11 (47.8) |
PAH associated with other conditionsb | 20 (33.3) | 26 (43.3) | 6 (26.1) |
Associated with lung diseases | 4 (6.7) | 9 (15.0) | 1 (4.3) |
CTEPH | 14 (23.3) | 10 (16.7) | 3 (13.0) |
Miscellaneous | 1 (1.7) | 0 (0.0) | 2 (8.7) |
[n = 60] | [n = 60] | [n = 23] | |
NYHA functional class, n (%) | |||
II | 3 (10.3) | 4 (8.5) | 0 (0) |
III | 13 (44.8) | 18 (38.3) | 5 (38.5) |
IV | 13 (44.8) | 25 (53.2) | 8 (61.5) |
[n = 29] | [n = 47] | [n = 13] | |
Mean PAP, mmHg (95% CI) | 55 (51–58) | 57 (53–61) | 73 (65–82) |
[n = 50] | [n = 51] | [n = 21] | |
Mean cardiac output, L/min (95% CI) | 3.4 (3.1–3.7) | 3.6 (3.3–3.9) | 3.1 (2.5–3.7) |
[n = 49] | [n = 51] | [n = 21] | |
Mean PVR, dyn.s.cm−5 (95% CI) | 1287 (1134–1440) | 1143 (1016–1270) | 1824 (1538–2109) |
[n = 49] | [n = 51] | [n = 21] | |
Mean 6MWD, m (95% CI) | 276 (232–319) | 281 (245–317) | 222 (179–265) |
[n = 38] | [n = 48] | [n = 16] | |